The Mumbai-based Siro Clinpharm Pvt Ltd, one of the leading players in the Indian contract research industry, is planning to offer clinical trials for Indian pharmaceutical companies in overseas sites such as the US and Europe.

According to sources close to the development, the company\'s move comes in the wake of more and more domestic pharmaceutical companies\' entry into new chemical entity (NCE) research. Domestic companies such as Ranbaxy, Glenmark and Wockhardt are already into the NCE research and out-licensing molecules to the foreign players. Most of these companies are out-licensing their molecules at the stage of phase II trials, which required to be conducted in various countries in Europe, North America and Japan.

\"Siro\'s move will enable Indian drug companies to conduct trials in several countries, especially in regulated markets through a single agency. It would also facilitate the companies to conduct trials as per the latest developments in these markets, as Indian (clinical research organisations) CROs are well aware of the developments in these countries. Moreover, it would also enable the Indian companies to save 25 per cent clinical trial costs\", people close to the development said.

Siro Clinpharm has already chalked out plans to expand its overseas presence into the Europe through an acquisition and the deal is expected to finalise shortly. It is part of company\'s global expansion strategy to conduct trials in different geographical locations. The acquisition would enable Siro to conduct trials in various gene pools. Some of the trials required to be conducted in various gene pools, as the companies are present in different countries.

The company offers a comprehensive array of phase I through phase IV clinical research services to clients in India. It also provides a complete selection of clinical research support from clinical trial development through final report and regulatory submission.